In our study, lung cancer patients harboring ABCB1 2677 and 3435 site wild‐type had longer median PFS in the paclitaxel treatment group, which was consistent with the results in gastric cancer.9 In prostate cancer,15 patients carrying the 2677T‐3435T haplotype had a shorter median survival in the docetaxel treatment group (P = 0.045), which also confirmed our finding that ABCB1 2677 and 3435 site wild‐type is a positive prognostic factor. This evidence concerns the gene ABCB1 and prostate cancer.